Research programme: antibacterials - Aviragen Therapeutics

Drug Profile

Research programme: antibacterials - Aviragen Therapeutics

Alternative Names: Benzothiazole urea based inhibitors - Aviragen Therapeutics; CDI-538 series antibacterials - Prolysis; CDI-936 series antibacterials - Prolysis; GYR-767 series antibacterials - Prolysis; PC-190708; PC-190723

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Prolysis
  • Developer Aviragen Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Small molecules
  • Mechanism of Action Cell division inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Clostridium infections; Pneumonia; Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
  • 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
  • 12 Sep 2012 Antimicrobial data from a preclinical trial in Bacterial infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top